Halozyme Therapeutics Completes Enrollment In Chemophase Phase I/IIa Clinical Trial For Superficial Bladder Cancer

September 26th, 2007 | Category: Cancer

Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, announced that enrollment is complete in its Chemophase(R) Phase I/IIa clinical trial for the treatment of superficial bladder cancer. The Company began dosing patients in

that trial in April of last year, following the successful completion of the initial Phase I trial of a single-administration of Chemophase and mitomycin. [click link for full article]

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint In Phase I/IIa Clinical Trial
  • Metabasis Completes Enrollment Of Its Proof-of-Concept Clinical Trial For MB07803, Its Product Candidate For The Treatment Of Type 2 Diabetes
  • CombinatoRx Completes Enrollment In Phase 2B Clinical Trial Of CRx-102 In Knee Osteoarthritis
  • NicOx Completes Patient Enrollment In Third Naproxcinod Pivotal Phase 3 Study
  • VioQuest Pharmaceuticals Completes Enrollment Of Phase I Trial Of Lenocta(TM)

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.